Insider Selling: Sera Prognostics (NASDAQ:SERA) CFO Sells 5,440 Shares of Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CFO Austin Aerts sold 5,440 shares of Sera Prognostics stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $2.08, for a total value of $11,315.20. Following the completion of the transaction, the chief financial officer owned 303,227 shares of the company’s stock, valued at approximately $630,712.16. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Sera Prognostics Trading Down 6.1%

Shares of NASDAQ SERA traded down $0.13 during mid-day trading on Wednesday, hitting $2.00. The company had a trading volume of 99,259 shares, compared to its average volume of 58,147. The company has a market capitalization of $78.32 million, a price-to-earnings ratio of -3.08 and a beta of 0.94. Sera Prognostics, Inc. has a 1 year low of $1.43 and a 1 year high of $4.09. The stock’s 50-day moving average price is $2.03 and its 200-day moving average price is $2.56.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.01). The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.07 million. Sera Prognostics had a negative net margin of 56,385.97% and a negative return on equity of 41.02%. As a group, equities research analysts forecast that Sera Prognostics, Inc. will post -0.58 earnings per share for the current year.

Institutional Investors Weigh In On Sera Prognostics

Large investors have recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC bought a new stake in Sera Prognostics during the fourth quarter worth about $31,000. Arkadios Wealth Advisors bought a new stake in Sera Prognostics during the first quarter worth about $25,000. Vanguard Personalized Indexing Management LLC bought a new stake in Sera Prognostics during the third quarter worth about $38,000. Lido Advisors LLC bought a new stake in Sera Prognostics during the third quarter worth about $68,000. Finally, Cetera Investment Advisers bought a new stake in Sera Prognostics during the fourth quarter worth about $74,000. Institutional investors own 54.64% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on SERA. Craig Hallum began coverage on Sera Prognostics in a research note on Thursday, June 4th. They set a “buy” rating and a $6.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Sera Prognostics in a research note on Friday, March 27th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $5.50.

Sera Prognostics Company Profile

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.